Search Results: Treatment + Breast Cancer + Stage 2 or 3 (3 results)
Treating Early-Stage HER2-Negative Breast Cancer with a PARP Inhibitor (Niraparib) and Immunotherapy (Dostarlimab) in People with a BRCA or PALB2 Mutation
https://www.facingourrisk.org/research-clinical-trials/study/158/treating-early-stage-breast-cancer-with-a-parp-inhibitor-niraparib-and-immunotherapy-dostarlimab-in-people-with-a-brca-or-palb2-mutation
Treatment
Treatment before surgery for people with early-stage breast cancer & a BRCA1, BRCA2 or PALB2 mutation
This study will look at how well the drugs Niraparib (a PARP inhibitor) and Dostarlimab (an immunotherapy) treat early-stage breast cancer in people with an inherited BRCA1, BRCA2 or PALB2 mutation.
Using ctDNA Blood Test to Screen for Cancer DNA after Treatment for Early-Stage TNBC and/or an Inherited or Tumor BRCA Mutation; Followed by Study Comparing Niraparib with Placebo for People with Cancer DNA found in their Blood (ZEST)
https://www.facingourrisk.org/research-clinical-trials/study/170/screening-for-cancer-dna-in-the-blood-after-treatment-for-early-stage-tnbc-andor-a-brca-mutation-followed-by-study-comparing-niraparib-with-placebo-for-people-with-cancer-dna-found-in-their-blood-zest
Treatment
Early-stage TNBC or early-stage breast cancer with a BRCA mutation
This study will enroll people with early-stage triple negative breast cancer or people with an inherited or acquired BRCA1 or BRCA2 mutation who have completed treatment (or are still in treatment with hormone therapy) for screening using a blood test known as circulating tumor DNA (ctDNA). Individuals who test positive for ctDNA may be eligible to participate in a randomized study to receive the PARP inhibitor, niraparib or a placebo and undergo close monitoring with imaging (CT scans). The study will look at the safety and efficacy of niraparib plus monitoring compared with placebo plus monitoring for people who test positive for cancer cells in their blood but who have no evidence of cancer recurrence.
Pragmatic Randomized Trial of Proton vs. Photon Therapy for Patients with Non-Metastatic Breast Cancer Receiving Comprehensive nodal Radiation: A Radiotherapy Comparative Effectiveness Trial
https://www.facingourrisk.org/research-clinical-trials/study/56/radcomp-a-study-at-the-heart-of-breast-cancer-treatment
Treatment
The RadComp Study, short for Radiotherapy Comparative Effectiveness, is a nationwide clinical study comparing two FDA approved radiation therapies for the treatment of breast cancer, PHoton Therapy vs. PRoton Therapy. With any radiation treatment to the breast, the heart may be exposed to radiation potentially resulting in heart problems in the future. Both Photon and Proton therapies are FDA approved; however, to date doctors do not know which therapy is better or worse in terms of reducing side effects and promoting length and quality of life after radiation.
We hope to learn: The effectiveness of proton vs. photon therapy in reducing major cardiovascular events and how treatment affects patient’s quality of life, such as financial burden, fatigue, and anxiety. These objectives were chosen as study priorities by breast cancer patients themselves.
Additional Results on Clinicaltrials.gov Treatment + Breast Cancer + Stage 2 or 3
78 results
Partial Chest Wall Radiation Therapy After Surgery for Lymph Node Negative Breast Cancer
NCT ID: NCT05436808 (https://ClinicalTrials.gov/show/NCT05436808)
Assessing the Rate of Complications in X-Ray Therapy Versus Proton Beam Radiation Therapy After Breast Conserving Surgery or Mastectomy in Treating Patients With Breast Cancer
NCT ID: NCT04443413 (https://ClinicalTrials.gov/show/NCT04443413)
Radiation Therapy Boost Before Surgery for the Treatment of Non-metastatic Breast Cancer
NCT ID: NCT04871516 (https://ClinicalTrials.gov/show/NCT04871516)
Abemaciclib in Treating Patients With Surgically Resectable, Chemotherapy Resistant, Triple Negative Breast Cancer
NCT ID: NCT03979508 (https://ClinicalTrials.gov/show/NCT03979508)
SABR-CaRe in Early Stage Breast Cancer
NCT ID: NCT04959474 (https://ClinicalTrials.gov/show/NCT04959474)
Hypofractionated Radiation Therapy in Treating Patients With Stage 0-IIB Breast Cancer
NCT ID: NCT03345420 (https://ClinicalTrials.gov/show/NCT03345420)
HER2 Directed Dendritic Cell Vaccine During Neoadjuvant Therapy of HER2+Breast Cancer
NCT ID: NCT03387553 (https://ClinicalTrials.gov/show/NCT03387553)
Personalized Neo-Antigen Peptide Vaccine for the Treatment of Stage IIIC-IV Melanoma or Hormone Receptor Positive Her2 Negative Metastatic Refractory Breast Cancer
NCT ID: NCT05098210 (https://ClinicalTrials.gov/show/NCT05098210)
Intraoperative Radiation Therapy in Treating Patients With Breast Cancer Undergoing Breast-Conserving Surgery
NCT ID: NCT01570998 (https://ClinicalTrials.gov/show/NCT01570998)
Enzalutamide and Paclitaxel Before Surgery in Treating Patients With Stage I-III Androgen Receptor-Positive Triple-Negative Breast Cancer
NCT ID: NCT02689427 (https://ClinicalTrials.gov/show/NCT02689427)
RBX7455 Before Surgery for the Treatment of Operable Breast Cancer
NCT ID: NCT04139993 (https://ClinicalTrials.gov/show/NCT04139993)
Concurrent WOKVAC Vaccination, Chemotherapy, and HER2-Targeted Monoclonal Antibody Therapy Before Surgery for the Treatment of Patients With Breast Cancer
NCT ID: NCT04329065 (https://ClinicalTrials.gov/show/NCT04329065)
Radiation Therapy in Treating Patients With Stage 0-II Breast Cancer
NCT ID: NCT01245712 (https://ClinicalTrials.gov/show/NCT01245712)
Testing the Addition of an Anti-cancer Drug, ASTX727 (Cedazuridine, Decitabine), to Chemotherapy (Paclitaxel) and Immunotherapy (Pembrolizumab) for Metastatic Triple-Negative Breast Cancer
NCT ID: NCT05673200 (https://ClinicalTrials.gov/show/NCT05673200)
Standard Verbal Counseling With or Without a Pictorial Educational Tool for the Reduction of Psychological Morbidity in Patients With Stage 0-IIIA Breast Cancer Receiving Radiation Therapy, COPE Study
NCT ID: NCT04993313 (https://ClinicalTrials.gov/show/NCT04993313)
Panitumumab and Pembrolizumab in Combination With Neoadjuvant Chemotherapy for the Treatment of Stage III-IV Triple Negative Breast Cancer
NCT ID: NCT05177796 (https://ClinicalTrials.gov/show/NCT05177796)
Converting HR+ Breast Cancer Into an Individualized Vaccine
NCT ID: NCT03804944 (https://ClinicalTrials.gov/show/NCT03804944)
TPIV100 and Sargramostim for the Treatment of HER2 Positive, Stage II-III Breast Cancer in Patients With Residual Disease After Chemotherapy and Surgery
NCT ID: NCT04197687 (https://ClinicalTrials.gov/show/NCT04197687)
CompassHER2-pCR: Decreasing Chemotherapy for Breast Cancer Patients After Pre-surgery Chemo and Targeted Therapy
NCT ID: NCT04266249 (https://ClinicalTrials.gov/show/NCT04266249)
Optical Spectroscopy in Evaluating Tumor Margins in Patients Who Have Undergone Surgery for Breast Tumors
NCT ID: NCT00625417 (https://ClinicalTrials.gov/show/NCT00625417)
A Study of Oleogel-S10 Gel for the Treatment of Radiation Dermatitis in People With Breast Cancer
NCT ID: NCT05190770 (https://ClinicalTrials.gov/show/NCT05190770)
Adjuvant Therapy With an Alpha-lactalbumin Vaccine in Triple-Negative Breast Cancer
NCT ID: NCT04674306 (https://ClinicalTrials.gov/show/NCT04674306)
Treatment of Frailty With Fisetin (TROFFi) in Breast Cancer Survivors
NCT ID: NCT05595499 (https://ClinicalTrials.gov/show/NCT05595499)
Hypofractionated vs. Conventional Regional Nodal Radiation Therapy for Patients With Invasive Breast Cancer
NCT ID: NCT02912312 (https://ClinicalTrials.gov/show/NCT02912312)
Abemaciclib and Niraparib Before Surgery for the Treatment of Hormone Receptor Positive HER2 Negative Breast Cancer
NCT ID: NCT04481113 (https://ClinicalTrials.gov/show/NCT04481113)
STEMVAC in Patients With Early Stage Triple Negative Breast Cancer
NCT ID: NCT05455658 (https://ClinicalTrials.gov/show/NCT05455658)
Testing the Addition of Anti-Cancer Drug, ZEN003694 (ZEN-3694) and PD-1 Inhibitor (Pembrolizumab), to Standard Chemotherapy (Nab-Paclitaxel) Treatment in Patients With Advanced Triple-Negative Breast Cancer
NCT ID: NCT05422794 (https://ClinicalTrials.gov/show/NCT05422794)
Study of a Shortened Radiation Therapy Schedule in People With Breast Cancer
NCT ID: NCT04648904 (https://ClinicalTrials.gov/show/NCT04648904)
Effects of Probiotics on the Gut Microbiome and Immune System in Operable Stage I-III Breast or Lung Cancer
NCT ID: NCT04857697 (https://ClinicalTrials.gov/show/NCT04857697)
Anastrozole and Letrozole After Surgery for the Treatment of Stage I-III Breast Cancer
NCT ID: NCT04294225 (https://ClinicalTrials.gov/show/NCT04294225)
Monitoring Symptoms to Help Young Women Take Hormone Therapy for Stage I-III Breast Cancer, ASPEN Study
NCT ID: NCT05568472 (https://ClinicalTrials.gov/show/NCT05568472)
Effect of HSD3B1 (1245C) Gene Mutation on Treatment of Stage I-III Breast Cancer
NCT ID: NCT05183828 (https://ClinicalTrials.gov/show/NCT05183828)
Trastuzumab Deruxtecan Alone or in Combination With Anastrozole for the Treatment of Early Stage HER2 Low, Hormone Receptor Positive Breast Cancer
NCT ID: NCT04553770 (https://ClinicalTrials.gov/show/NCT04553770)
Women's MoonShot: Neoadjuvant Treatment With PaCT for Patients With Locally Advanced TNBC
NCT ID: NCT02593175 (https://ClinicalTrials.gov/show/NCT02593175)
Platelet Rich Plasma for the Treatment of Genitourinary Syndrome of Menopause in Patients With Stage 0-III Breast Cancer
NCT ID: NCT04535323 (https://ClinicalTrials.gov/show/NCT04535323)
Feasibility Study of Biobehavioral Stress Reduction Intervention in Patients With Triple Negative Breast Cancer
NCT ID: NCT05677802 (https://ClinicalTrials.gov/show/NCT05677802)
Eliminating Surgery or Radiotherapy After Systemic Therapy in Treating Patients With HER2 Positive or Triple Negative Breast Cancer
NCT ID: NCT02945579 (https://ClinicalTrials.gov/show/NCT02945579)
Ribociclib, Tucatinib, and Trastuzumab for the Treatment of HER2 Positive Breast Cancer
NCT ID: NCT05319873 (https://ClinicalTrials.gov/show/NCT05319873)
Hypofractionated Partial Breast Irradiation in Treating Patients With Early Stage Breast Cancer
NCT ID: NCT03077841 (https://ClinicalTrials.gov/show/NCT03077841)
PET/CT in Evaluating Response to Chemotherapy in Patients With Breast Cancer
NCT ID: NCT01712815 (https://ClinicalTrials.gov/show/NCT01712815)
TAEK-VAC-HerBy Vaccine for Brachyury and HER2 Expressing Cancer
NCT ID: NCT04246671 (https://ClinicalTrials.gov/show/NCT04246671)
Improving Patient-Centered Communication in Breast Cancer Through Patient and Provider Interventions
NCT ID: NCT04549571 (https://ClinicalTrials.gov/show/NCT04549571)
Testing the Combination of the Anti-cancer Drugs XL184 (Cabozantinib) and Nivolumab in Patients With Advanced Cancer and HIV
NCT ID: NCT04514484 (https://ClinicalTrials.gov/show/NCT04514484)
FASN Inhibitor TVB-2640 and Trastuzumab in Combination With Paclitaxel or Endocrine Therapy for the Treatment of HER2 Positive Metastatic Breast Cancer
NCT ID: NCT03179904 (https://ClinicalTrials.gov/show/NCT03179904)
T-VEC With Chemotherapy or Endocrine Therapy in Treating Participants With HER2- Negative Breast Cancer
NCT ID: NCT03554044 (https://ClinicalTrials.gov/show/NCT03554044)
Pembrolizumab in Treating Participants With Metastatic, Recurrent or Locally Advanced Cancer and Genomic Instability
NCT ID: NCT03428802 (https://ClinicalTrials.gov/show/NCT03428802)
Clinical Trial Assessing the Safety of Neoadjuvant Palbociclib in Combination With Endocrine Therapy
NCT ID: NCT05069038 (https://ClinicalTrials.gov/show/NCT05069038)
Serial Measurements of Molecular and Architectural Responses to Therapy (SMMART) PRIME Trial
NCT ID: NCT03878524 (https://ClinicalTrials.gov/show/NCT03878524)
CLEVER Pilot Trial: A Phase II Pilot Trial of HydroxyChLoroquine, EVErolimus or the Combination for Prevention of Recurrent Breast Cancer
NCT ID: NCT03032406 (https://ClinicalTrials.gov/show/NCT03032406)
Niraparib and TSR-042 for the Treatment of BRCA-Mutated Unresectable or Metastatic Breast, Pancreas, Ovary, Fallopian Tube, or Primary Peritoneal Cancer
NCT ID: NCT04673448 (https://ClinicalTrials.gov/show/NCT04673448)
T-DM1 and Tucatinib Compared With T-DM1 Alone in Preventing Relapses in People With High Risk HER2-Positive Breast Cancer, the CompassHER2 RD Trial
NCT ID: NCT04457596 (https://ClinicalTrials.gov/show/NCT04457596)
Nilotinib in Preventing Paclitaxel-Induced Peripheral Neuropathy in Patients With Stage I-III Breast Cancer
NCT ID: NCT04205903 (https://ClinicalTrials.gov/show/NCT04205903)
Personalized Neoantigen Peptide-Based Vaccine in Combination With Pembrolizumab for the Treatment of Advanced Solid Tumors, The PNeoVCA Study
NCT ID: NCT05269381 (https://ClinicalTrials.gov/show/NCT05269381)
DNA-Guided Second Line Adjuvant Therapy For High Residual Risk, Stage II-III, Hormone Receptor Positive, HER2 Negative Breast Cancer
NCT ID: NCT04567420 (https://ClinicalTrials.gov/show/NCT04567420)
MARGetuximab Or Trastuzumab (MARGOT)
NCT ID: NCT04425018 (https://ClinicalTrials.gov/show/NCT04425018)
Safely Stopping Pre-medications in Patients With Breast Cancer Who Are Receiving Paclitaxel
NCT ID: NCT04862585 (https://ClinicalTrials.gov/show/NCT04862585)
Olaparib With Cediranib or AZD6738 for the Treatment of Advanced or Metastatic Germline BRCA Mutated Breast Cancer
NCT ID: NCT04090567 (https://ClinicalTrials.gov/show/NCT04090567)
Molecular Testing and Imaging in Improving Response in Patients With Stage I-III Triple-Negative Breast Cancer Receiving Chemotherapy MDACC Breast Moonshot Initiative
NCT ID: NCT02276443 (https://ClinicalTrials.gov/show/NCT02276443)
Testing the Addition of Copanlisib to Eribulin for the Treatment of Advanced-Stage Triple Negative Breast Cancer
NCT ID: NCT04345913 (https://ClinicalTrials.gov/show/NCT04345913)
Testing the Combination of Two Anti-cancer Drugs, DS-8201a and AZD6738, for The Treatment of Patients With Advanced Solid Tumors Expressing the HER2 Protein or Gene, The DASH Trial
NCT ID: NCT04704661 (https://ClinicalTrials.gov/show/NCT04704661)
Tumor Treating Fields Therapy in Combination With Chemotherapy for the Treatment of Advanced Solid Tumors Involving the Abdomen or Thorax
NCT ID: NCT05092373 (https://ClinicalTrials.gov/show/NCT05092373)
Niraparib + Dostarlimab In BRCA Mutated Breast Cancer
NCT ID: NCT04584255 (https://ClinicalTrials.gov/show/NCT04584255)
Avelumab With Binimetinib, Sacituzumab Govitecan, or Liposomal Doxorubicin in Treating Patients With Stage IV or Unresectable, Recurrent Triple Negative Breast Cancer
NCT ID: NCT03971409 (https://ClinicalTrials.gov/show/NCT03971409)
Efficacy & Safety Evaluation of Enobosarm in Combo With Abemaciclib in Treatment of ER+HER2- Metastatic Breast Cancer
NCT ID: NCT05065411 (https://ClinicalTrials.gov/show/NCT05065411)
A Dose-escalation Study of the Safety and Pharmacology of DAN-222 in Subjects With Metastatic Breast Cancer
NCT ID: NCT05261269 (https://ClinicalTrials.gov/show/NCT05261269)
To Evaluate the Safety, Tolerability, and Pharmacokinetics of Inavolisib Single Agent in Participants With Solid Tumors and in Combination With Endocrine and Targeted Therapies in Participants With Breast Cancer
NCT ID: NCT03006172 (https://ClinicalTrials.gov/show/NCT03006172)
Researching the Effect of Exercise on Cancer
NCT ID: NCT04589468 (https://ClinicalTrials.gov/show/NCT04589468)
(Z)-Endoxifen for the Treatment of Premenopausal Women With ER+/HER2- Breast Cancer
NCT ID: NCT05607004 (https://ClinicalTrials.gov/show/NCT05607004)
Estradiol in Treating Patients With ER Beta Positive, Triple Negative Locally Advanced or Metastatic Breast Cancer
NCT ID: NCT03941730 (https://ClinicalTrials.gov/show/NCT03941730)
Testing the Addition of an Anti-cancer Drug, BAY 1895344, to the Usual Chemotherapy Treatment (Cisplatin, or Cisplatin and Gemcitabine) for Advanced Solid Tumors With Emphasis on Urothelial Cancer
NCT ID: NCT04491942 (https://ClinicalTrials.gov/show/NCT04491942)
ALRN-6924 and Paclitaxel in Treating Patients With Advanced, Metastatic, or Unresectable Solid Tumors
NCT ID: NCT03725436 (https://ClinicalTrials.gov/show/NCT03725436)
Letrozole With and Without Simvastatin for the Treatment of Stage I-III Hormone Receptor Positive, HER2 Negative Breast Cancer
NCT ID: NCT05464810 (https://ClinicalTrials.gov/show/NCT05464810)
A Study Evaluating the Efficacy and Safety of Multiple Treatment Combinations in Participants With Breast Cancer
NCT ID: NCT04802759 (https://ClinicalTrials.gov/show/NCT04802759)
Doxorubicin Hydrochloride and Cyclophosphamide Followed by Paclitaxel With or Without Carboplatin in Treating Patients With Triple-Negative Breast Cancer
NCT ID: NCT02488967 (https://ClinicalTrials.gov/show/NCT02488967)
Measuring the Effects of Talazoparib in Patients With Advanced Cancer and DNA Repair Variations
NCT ID: NCT04550494 (https://ClinicalTrials.gov/show/NCT04550494)
Selinexor With Multiple Standard Chemotherapy or Immunotherapy Regimens in Treating Patients With Advanced Malignancies
NCT ID: NCT02419495 (https://ClinicalTrials.gov/show/NCT02419495)
Avapritinib for the Treatment of CKIT or PDGFRA Mutation-Positive Locally Advanced or Metastatic Malignant Solid Tumors
NCT ID: NCT04771520 (https://ClinicalTrials.gov/show/NCT04771520)
Dose Escalation and Expansion Study of FLX475 Monotherapy and in Combination With Pembrolizumab
NCT ID: NCT03674567 (https://ClinicalTrials.gov/show/NCT03674567)
About FORCE
FORCE is a national nonprofit organization, established in 1999. Our mission is to improve the lives of individuals and families affected by adult hereditary cancers.